Prevalence, risk factors, and vaccine effectiveness of COVID-19 infection in thai children, adolescents, and young adults in the omicron era.
COVID-19
Omicron
adolescents
children
risk factors
vaccine effectiveness
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
02
2023
accepted:
26
04
2023
medline:
26
5
2023
pubmed:
26
5
2023
entrez:
26
5
2023
Statut:
epublish
Résumé
The study of prevalence, risk factors, and vaccine effectiveness (VE) in children, adolescents, and young adults during the Omicron era has been limited, making this the objectives of the study. A prospective, test-negative case-control study was conducted on patients aged 0-24 years old classified as patients under investigation (PUI) from January to May 2022. PUI with positive RT-PCR within 14 days were classified as cases, whilst PUI with negative RT-PCR in 14 days were controls. Univariate and multivariate analyses determined risk factors; VE was calculated using [1-adjusted odds ratio (OR)] × 100. The final analyses included 3,490 patients with a PUI infection rate of 45.6%. Heterologous vaccination regimens, including inactivated vaccines, viral vectors, and mRNA were utilized during the study period. A total of 2,563 patients (73.5%) had received at least 2 vaccine doses, regardless of regimen. Male gender and household infections were independent risk factors for the development of infection, with an adjusted OR of 1.55 and 1.45, respectively. Underlying comorbidities and obesity were not significantly associated with the development of infection. Patients with underlying comorbidities were more likely to have at least moderate severity of infection with the adjusted OR of 3.07. Age older than 11 years was associated with lower infection risk and development of at least moderate infection with adjusted OR of 0.4 and 0.34, respectively. Vaccinated participants also had a lower risk of developing at least moderate infection: adjusted OR of 0.40. The adjusted VE of any vaccination regimen for infection prevention for one, two, three, or more than four doses was 21.8%, 30.6%, 53.5%, and 81.2%, respectively. The adjusted VE of any vaccination regimen for prevention of at least moderate severity of the disease for one, two, three, or more than four doses was 5.7%, 24.3% 62.9%, and 90.6%, respectively. Disease prevalence among PUI was substantially high during the Omicron wave. A two-dose vaccination regimen does not appear sufficient to ensure protection against infection.
Sections du résumé
Background and objectives
UNASSIGNED
The study of prevalence, risk factors, and vaccine effectiveness (VE) in children, adolescents, and young adults during the Omicron era has been limited, making this the objectives of the study.
Methods
UNASSIGNED
A prospective, test-negative case-control study was conducted on patients aged 0-24 years old classified as patients under investigation (PUI) from January to May 2022. PUI with positive RT-PCR within 14 days were classified as cases, whilst PUI with negative RT-PCR in 14 days were controls. Univariate and multivariate analyses determined risk factors; VE was calculated using [1-adjusted odds ratio (OR)] × 100.
Results
UNASSIGNED
The final analyses included 3,490 patients with a PUI infection rate of 45.6%. Heterologous vaccination regimens, including inactivated vaccines, viral vectors, and mRNA were utilized during the study period. A total of 2,563 patients (73.5%) had received at least 2 vaccine doses, regardless of regimen. Male gender and household infections were independent risk factors for the development of infection, with an adjusted OR of 1.55 and 1.45, respectively. Underlying comorbidities and obesity were not significantly associated with the development of infection. Patients with underlying comorbidities were more likely to have at least moderate severity of infection with the adjusted OR of 3.07. Age older than 11 years was associated with lower infection risk and development of at least moderate infection with adjusted OR of 0.4 and 0.34, respectively. Vaccinated participants also had a lower risk of developing at least moderate infection: adjusted OR of 0.40. The adjusted VE of any vaccination regimen for infection prevention for one, two, three, or more than four doses was 21.8%, 30.6%, 53.5%, and 81.2%, respectively. The adjusted VE of any vaccination regimen for prevention of at least moderate severity of the disease for one, two, three, or more than four doses was 5.7%, 24.3% 62.9%, and 90.6%, respectively.
Conclusion
UNASSIGNED
Disease prevalence among PUI was substantially high during the Omicron wave. A two-dose vaccination regimen does not appear sufficient to ensure protection against infection.
Identifiants
pubmed: 37234858
doi: 10.3389/fped.2023.1173162
pmc: PMC10206128
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1173162Informations de copyright
© 2023 Chaiyakulsil, Sritipsukho, Satdhabudha, Bunjoungmanee, Tangsathapornpong, Sinlapamongkolkul and Sritipsukho.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2022 May 19;386(20):1899-1909
pubmed: 35353976
Lancet. 2021 Dec 4;398(10316):2093-2100
pubmed: 34756184
J Med Virol. 2021 Feb;93(2):1057-1069
pubmed: 32761898
Epidemiol Serv Saude. 2021 Sep 22;30(4):e20201029
pubmed: 34586293
Nat Commun. 2022 Aug 13;13(1):4756
pubmed: 35963844
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Mediterr J Hematol Infect Dis. 2022 May 01;14(1):e2022044
pubmed: 35615321
Vaccines (Basel). 2022 Jul 05;10(7):
pubmed: 35891245
IJID Reg. 2021 Dec;1:159-162
pubmed: 35721777
N Engl J Med. 2022 Jul 21;387(3):227-236
pubmed: 35767475
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1731-1734
pubmed: 34914670
EClinicalMedicine. 2020 Jun 26;24:100433
pubmed: 32766542
Emerg Microbes Infect. 2022 Dec;11(1):585-592
pubmed: 35114893
Pediatrics. 2020 Oct;146(4):
pubmed: 32665373
PLoS One. 2022 Apr 15;17(4):e0267035
pubmed: 35427379
N Engl J Med. 2022 Aug 11;387(6):525-532
pubmed: 35857701
PLoS One. 2020 Sep 15;15(9):e0239250
pubmed: 32931517
Int J Infect Dis. 2021 Feb;103:246-256
pubmed: 33227520
Am J Trop Med Hyg. 2021 Jun 15;105(2):413-420
pubmed: 34129517
Bull World Health Organ. 2007 Sep;85(9):660-7
pubmed: 18026621